iRegene's NouvSight001 Cell Therapy Cleared for Retinitis Pigmentosa Trials in U.S. and China
核心洞察
China's NMPA cleared iRegene Therapeutics (搜索)' NouvSight001 for a Phase I/III trial in retinitis pigmentosa (搜索), evaluating safety, tolerability and preliminary efficacy.
The FDA cleared the same allogeneic photoreceptor cell therapy for a Phase I/II trial in the same indication and granted a special exemption.
NouvSight001 is an off-the-shelf cell replacement therapy made with iRegene's AI plus chemical induction platform and is not limited to one causative genotype.
iRegene Therapeutics (搜索) has received clinical trial clearances in both the United States and China for NouvSight001, an allogeneic, off-the-shelf photoreceptor cell therapy for retinitis pigmentosa (搜索) (RP). China's National Medical Products Administration (搜索) cleared the investigational therapy for a Phase I/III trial evaluating safety, tolerability and preliminary efficacy in patients with RP. The U.S. Food and Drug Administration (搜索) cleared NouvSight001 for a Phase I/II trial in the same indication and granted a special exemption.
The Chengdu-based company announced the clearances on Sept. 29, 2026. The program follows iRegene's Parkinson's disease (搜索) cell therapy into international clinical development and expands the company's pipeline into retinal regenerative medicine.
A Genotype-Agnostic Cell Replacement Approach
NouvSight001 was developed using iRegene's proprietary "AI + Chemical Induction" ("AI + Chem") platform. As a cell replacement therapy, it is not limited to patients with a specific disease-causing genotype, a distinction that matters in a genetically heterogeneous disease.
The AI + Chem platform is designed to identify and characterize key biological networks that determine cell fate and function, and to precisely regulate those networks using small molecules. Through this approach, iRegene aims to make complex cell differentiation processes more predictable, controllable, reproducible and scalable for therapeutic manufacturing.
The company describes the NouvSight001 clearances as another step toward a "one platform, multiple products, global development" model, in which multiple candidates generated from the same platform move into international clinical development across different cell types and disease areas.
Regulatory Path and Prior Designation
NouvSight001 received FDA Orphan Drug Designation in 2024. With the NMPA and FDA clearances plus the FDA special exemption, the program now holds regulatory authorizations on both sides of the Pacific.
iRegene frames these clearances as evidence of its ability to advance internally developed therapies into U.S. clinical development under global regulatory and development standards. The company points to shared capabilities across its programs: global regulatory strategy; CMC and quality systems built to meet FDA and NMPA requirements; manufacturing for allogeneic, off-the-shelf cell therapies; cross-border cold-chain and supply-chain operations; clinical development in the U.S. and China; and an R&D platform designed to continuously generate new therapeutic candidates.
"Globalization has been embedded in our R&D system since the company was founded," said Tianshi Ruan, Chief Financial Officer of iRegene Therapeutics (搜索). "NouvNeu001 has given us hands-on experience advancing an iPSC-derived cell therapy across both the NMPA and FDA regulatory frameworks. NouvSight001 allows us to apply that experience to ophthalmology, a very different disease and tissue setting."
"The same underlying technology platform allows us to advance our pipeline globally and more efficiently," Ruan added. "Going forward, we will continue to advance our core programs in clinical development in the U.S. and China, while actively exploring global multicenter studies and international commercial partnerships."
Pipeline Spanning CNS, Vision and Neurovascular Disease
iRegene has built a regenerative medicine pipeline focused on diseases associated with the structural burden of an aging global population, including Parkinson's disease (搜索), multiple system atrophy (搜索), retinal degenerative diseases and ischemic stroke (搜索). The pipeline now spans the central nervous system, visual system and neurovascular system.
Rather than developing a single cell therapy, the company aims to build a technology platform capable of continuously generating new regenerative medicine products. Its programs seek to restore functions lost to disease, including neural circuits and vision, and to repair damaged neural tissue.
Unmet Need in Retinitis Pigmentosa
Retinitis pigmentosa (搜索) is a group of inherited retinal degenerative diseases affecting approximately 1.5 million people worldwide. It typically begins with night blindness and progresses to peripheral vision loss and, in some cases, blindness.
The only approved therapy is limited to patients with biallelic RPE65 (搜索) mutations, who represent a small fraction of the RP population. Most patients still have no disease-modifying treatment options, leaving a broad population for whom cell replacement approaches such as NouvSight001 are being explored.